Respiratory Market Insight 2008

This brand new report examines the forthcoming prospects for respiratory drugs over the next 5 year. With in-depth sales forecasts for leading pharmaceutical products, the report has been produced to inform you of future developments and strategies. The respiratory market generated revenues of $30503m in 2006, but what will it be in 2013? Which year the market will reach its peak? This report tells you.

The prevalence of respiratory diseases such as asthma, in the leading pharmaceutical markets, has increased significantly over the past few decades. Although there is some evidence to suggest that the rate of increase is slowing, we believe that the prevalence will continue to increase and be a key driver of this market throughout the forecast period of the report.

The respiratory market contained ten blockbuster drugs in 2006, with the top three being: Advair/Seretide, Singulair and Zyrtec. Visiongain predicts that there will be room for more blockbusters as the current products lose patent protection.

This detailed report highlights as well pipeline developments and important contemporary issues, especially commercial drivers and restraints. Sources include primary interviews and analysis unavailable elsewhere, in-house industry databases, commercial news, published reports, economic research and consultation with experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

In particular, The Respiratory Market concentrates on the following essential aspects of the market:

• Discussion of the current pharmaceutical market

• Forecast of the worldwide pharmaceutical market from 2008-2013

• Drivers and restraints facing the respiratory market

• Opportunities and threats facing the respiratory market

• Growth of the respiratory drugs market between 2008 and 2013

• Commercial prospects for the market-leading drugs, with sales forecasts from 2008-2013

• Individual forecasts of the leading drug classes from 2008-2013

• The potential of generics manufacturers to penetrate this market

• Pipeline developments with blockbuster potential

• Currently marketed drugs with blockbuster potential

• Discussion of unmet therapeutic needs and relative advantages of products

Do you know what the market values of these major therapeutic areas of the respiratory market are?

The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC respiratory drugs by product type. The study also assess' the challenges faced by respiratory companies, and what exciting market opportunities exist in this up- and-coming therapeutic area.

Why you should buy this report:

•To receive a comprehensive analysis of the prospects for respiratory drugs from 2008-2013

•To discover predicted revenues, growth rates and other key metrics for leading pharmaceutical treatments from 2008-2013

• To determine key activities of leading companies

• To discover “hot” pipeline developments and up-and-coming products

• To determine the forces that influence the market for respiratory products:

• Competitive characteristics of the market

• Drivers

• Restraints

• Strengths, weaknesses, opportunities and threats (SWOT analysis)

• To find out where the market is heading - both technologically and commercially

- PRICING-

- Single use licence $2,995.00

- Departmental copies (this entitles up to 5 individual users in your department) of this report are available for only USD$5,995.00. This is not suitable for library usage.

- Allow your whole company to have access to this information for only USD$9,995.00.

Company-wide License allows your whole company access and intranet use on CD Rom and .pdf. Suitable for library storage and use.

- Does your company have over 2,500 employees? Have the whole company access this information for a special rate of only USD$13,995.00

February 2008
Table of Contents

Price
Department Licence 5 Users $5,995.00
Company-wide Intranet Licence $9,995.00
Company over 2500 employees $13,995.00
Single Use Licence $2,995.00